SNDX
Syndax Pharmaceuticals Inc

3,774
Mkt Cap
$2.14B
Volume
23,648.00
52W High
$25.44
52W Low
$8.58
PE Ratio
-7.35
SNDX Fundamentals
Price
$24.23
Prev Close
$24.00
Open
$24.00
50D MA
$21.50
Beta
1.16
Avg. Volume
1.22M
EPS (Annual)
-$3.29
P/B
32.77
Rev/Employee
$578,362.42
$1,771.37
Loading...
Loading...
News
all
press releases
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Average Rating of "Moderate Buy" by Brokerages
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nin...
MarketBeat·6h ago
News Placeholder
More News
News Placeholder
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Hudson Bay Capital Management LP
Hudson Bay Capital Management LP decreased its position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 43.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 250,000 shares of the company's stock after selling 193,300 shares during the per...
MarketBeat·1d ago
News Placeholder
Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish
Key PointsKynam Capital reduced its Syndax Pharmaceuticals stake by 469,041 shares in the fourth quarter; the estimated trade size was $8.18 million based on average closing prices for the quarter...
Nasdaq News: Markets·2d ago
News Placeholder
Syndax Pharmaceuticals (NASDAQ:SNDX) Hits New 52-Week High - What's Next?
Syndax Pharmaceuticals (NASDAQ:SNDX) Reaches New 12-Month High - Here's What Happened...
MarketBeat·3d ago
News Placeholder
Kingdon Capital Management L.L.C. Purchases 400,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX
Kingdon Capital Management L.L.C. boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 19.0% in the third quarter, according to its most recent filing with...
MarketBeat·7d ago
News Placeholder
Granahan Investment Management LLC Has $6.10 Million Stock Position in Syndax Pharmaceuticals, Inc. $SNDX
Granahan Investment Management LLC reduced its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 60.0% in the third quarter, according to the company in its most recent Form 13F...
MarketBeat·7d ago
News Placeholder
Syndax Pharmaceuticals, Inc. $SNDX Shares Acquired by Boothbay Fund Management LLC
Boothbay Fund Management LLC boosted its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 103.3% in the 3rd quarter, according to its most recent disclosure with the...
MarketBeat·7d ago
News Placeholder
Apis Capital Advisors LLC Takes Position in Syndax Pharmaceuticals, Inc. $SNDX
Apis Capital Advisors LLC purchased a new position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) during the third quarter, according to its most recent 13F filing with the...
MarketBeat·8d ago
News Placeholder
Cancer Drug Maker With $172 Million Revenue and Multiple Approved Therapies Draws $6.5 Million Investment
Key PointsSphera Funds added 374,847 shares of Syndax Pharmaceuticals in the fourth quarter...
Nasdaq News: Markets·10d ago
News Placeholder
JPMorgan Chase & Co. Increases Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target to $45.00
JPMorgan Chase & Co. upped their price target on Syndax Pharmaceuticals from $33.00 to $45.00 and gave the stock an "overweight" rating in a research note on Monday...
MarketBeat·14d ago
<
1
2
...
>

Latest SNDX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.